5,5′′-Dibromo-1,1′′-bis­(prop-2-en-1-yl)-1,1′′,2,2′′-tetra­hydro­dispiro­[indole-3,7′-[6,9]diaza­tricyclo­[7.3.0.02,6]dodecane-8′,3′′-indole]-2,2′′-dione

In the mol­ecule of the title compound, C30H30Br2N4O2, the piperazine ring adopts a chair conformation. The pyrrolidine rings that are fused to the piperazine ring adopt envelope conformations (in which the N atom represents the flap). The indoline fused-ring systems are nearly planar (r.m.s. deviations = 0.009 and 0.019 Å); the two fused rings are aligned at 60.63 (6)°

1,1′-Dibenzyl-5,5′′-dichloro-1,1′′,2,2′′-tetra­hydro­dispiro­[indole-3,7′-[6,9]diaza­tricyclo­[7.3.0.02,6]dodecane-8′,3′′-indole]-2,2′′-dione

In the title compound, C38H34Cl2N4O2, the piperazine ring adopts a chair conformation. The pyrrolidine rings that are fused to the piperazine ring adopt envelope conformations (in which the C atoms connecting the two rings represent the flap). The indoline ring systems are approximately planar (r.m.s. deviations = 0.026 and 0.034 Å) and are aligned at a dihedral angle of 54.98 (3)°

Rare Presentation of Aggressive T/Natural Killer Lymphoproliferative Disorder in a Leukaemic Phase in an Omani Patient

N